Pablo Tebas the first author of the NEJM paper describing the Sangamo Biosciences sponsored work at UPENN titled " Gene Editiing of CCR5 in Autologous CD4 T-cells of persons affected with HIV" will speak today. The presentation is at the Clinical Research Forum.
The Clinical Research Forum was established in 1996 to provide a forum for discussions of the unique and complex challenges to clinical research among the senior clinical research leadership of leading academic health and science systems (AHASs). Over the past decade, it has convened these senior thought leaders in clinical research annually and has continued to provide a unique forum for discussion of common issues across the full spectrum of clinical and translational research.
There are slides posted online at http://www.clinicalresearchforum.org/vertical/Sites/%7B6D77AD78-8385-49EE-9E9C-158592F03CED%7D/uploads/Tebas_presentation.pdf
Slide 14 shows "Sustained Functional Control of Viral Load for More than One YEAR" !!!!!
Viral Load controlled more than 59 Weeks (less than 500 VL copies / mL)
Subject remains off ART !!!!
DURABLE FUNCTIONAL CONTROL ACHIEVED
Slide 20 shows "What we have learned"
It is DOABLE
The Size of the Reservoir Matters
The dose of the product (SB-728) matters
Mechanism ??
No comments:
Post a Comment